MediciNova completes last patient visit in COMBAT — ALS Phase 2b/3 trial of MN — 166 ibudilast

MediciNova completed the last patient, last visit in the double-blind portion of its COMBAT-ALS Phase 2b/3 trial of MN-166. Topline results have not been presented yet; release is expected by end-2026, with the full study’s final visit expected in March 2027. The update keeps the program on track for data lock and analysis, a key step toward potential late-stage regulatory planning in ALS. The study is assessing whether MN-166 can slow overall disease worsening while maintaining an acceptable safety and tolerability profile. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via (Ref. ID: 202609240600PRIMZONEFULLFEED9832654) on September 24, 2026, and is solely responsible for the information contained therein. (C)